Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP5280
- Development stage
- Discontinued
- Lead developer
- Abeona Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AP5280 is a novel polymer-conjugated platinum-based chemotherapeutic agent developed for the treatment of solid tumors. It consists of a platinum (Pt) moiety covalently linked to the water-soluble, biocompatible copolymer N-(2-hydroxypropyl)methacrylamide (pHPMA), designed to enhance tumor accumulation via the enhanced permeability and retention effect. This formulation aims to increase therapeutic efficacy while reducing systemic toxicity compared to traditional platinum drugs like cisplatin and carboplatin. The drug acts as a DNA alkylating agent, forming DNA adducts that inhibit DNA replication and transcription, ultimately leading to cancer cell death. Clinical studies have shown that AP5280 allows higher dosing with reduced renal toxicity and myelosuppression relative to conventional platinum agents[1][5][6].
- Other names
- AP5280AP-5280AP 5280Polymer-conjugated platinum anticancer agent
02
Targets
DNA
Beyond the preview
Go deeper on AP5280.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP5280.